Pierre Blier

TL;DR: Continuation of esketamine nasal spray in addition to oral antidepressant treatment resulted in clinically meaningful superiority in delaying relapse compared with antidepressant plus placebo in patients with TRD in stable remission.

TL;DR: The present data confirm and extend those of previous electrophysiologic studies showing that an enhanced 5-HT synaptic transmission is a common end result of long-term administration of various types of antidepressant treatments and suggest that the mechanisms underlying this enhanced synaptic transmission differ according to the type of treatment administered.

TL;DR: It was observed that the selective loss of DA neurons achieved by the intra-ventral tegmental area (VTA) injection of 6-OHDA increased the firing activity of a subset of locus coeruleus (LC) NE neurons, demonstrating a net inhibitory role of the NE input on VTA DA neurons.

TL;DR: That this adaptive change underlies, at least in part, the delayed therapeutic effect of SSRI in major depression is supported by the acceleration of the antidepressant response by the concomitant administration of the 5‐HT1A autoreceptor antagonist pindolol with SSRIs.

TL;DR: Emerging evidence from clinical studies with mirtazapine, venlafaxine and SSRI augmentation with pindolol suggests that these treatments may relieve antidepressant symptoms more rapidly than SSRIs.